GXGX News and Press, GX Acquisition From 05/05/21

Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes equity investment by Palantir in Celularity Investment, combined with...

GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination PR Newswire NEW YORK , April 16, 2021 /PRNewswire/ -- On April 14, 2021 , GX Acquisition Corp. ("GX") (NASDAQ: "GXGX"), provided information ...

BTIG analyst Thomas Shrader has initiated SPAC GX Acquisition Corp. (GXGX) with a buy rating and a $16 price target.Given yesterday close of $10.06, that represents an upside of 59%.GX's merger with Celularity Inc., a clinical-stage biotechnology company, was announced in January.Celular...

Aspira Women's Health (AWH) has extended the post-market gains with a ~12.2% rise in the pre-market as analysts weigh in on its new agreement to develop an early detection test for ovarian cancer.“We support the notion of the team taking another big swing and working to ...

After a ~9.9% rise in value yesterday, Sorrento Therapeutics (SRNE) has added another ~8.9% so far today, and an analyst from H.C. Wainwright estimates a price target of ~$30 for the stock, implying a ~275.0% upside to yesterday’s close.The analyst Ram Selvaraju pro...

GX Acquisition Corp. (GXGX) has agreed to combine with Celularity Inc., a clinical-stage biotechnology company. The transaction expected in Q2 2021 will make GX Acquisition Corp. being renamed Celularity Inc.The common stock and warrants of the special purpose acquisition company are exp...

Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy - Celularity has entered into a definitive merger agreement with GX Acquisition Corp. (Nasdaq: "GXGX"); upon closing, shares of the combined company wi...